On August 27, 2014, the newly built pharmaceutical plant of Beijing Huonland Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Huonland”), a controlling subsidiary of Beijing Northland Biotechnology Co., Ltd., obtained the “Drug Production License” issued by the Beijing Food and Drug Administration. The license is valid for five years. This marks that Huonland has basically met the requirements for drug production in terms of personnel, drug manufacturing, and drug quality management.

The newly built pharmaceutical plant was completed in July 2014. Its design, construction, and installation phases were all carried out strictly in accordance with China’s new GMP standards, while also meeting the requirements of both EU GMP and U.S. GMP standards. The company has also introduced from the United States two state-of-the-art, fully automated “blow-fill-seal” sterile production lines, each capable of producing both single-dose and multi-dose eye drops, with an annual production capacity reaching 110 million units.

Obtaining the production license represents a milestone in Huonland’s development. The company is currently expediting equipment commissioning and validation efforts, and will rigorously adhere to the requirements of China’s new GMP standards throughout the certification process. We aim to pass the new GMP certification in the first quarter of 2015, thereby ensuring that our pharmaceutical products can be officially produced and launched onto the market.